IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (956)	6/5/1997 6:54:00 PM
From: Brad C. Dunlap	of 1762

Hi Bennett, I sent you an e-mail yesterday but something tells me you didn't recieve my message. A few points that I can make in regards to CE9.1. 1] This study is a double blind placebo study, checked and confirmed as of yesterday that the first 100 patients have been treated and the study has not been unblinded. In other words nobody knows the results including smithKline. 2] SmithKline started this aggressive round of selling back in January and being that the study did not initiate until December and the second phase III in March also leaves one with confidence that smithkline's selling is unrelated to the study. 3] Since this study appears to be in good order then maybe there is info on T-cell depletion from previous studies. The following are the results of the previous studies with CE9.1. " Usual pattern of CD4+ T-cell response is initial drop immediately following infusion with recovery to baseline within 7 to 14 days. In phase I & II 4 of 245 patients were depressed for approx 4 months. 2 patients are below 250/mm[cubed] for 11 to 14 months. No adverse events or opportunitic infections related to low CD4 counts have been observed in any patient with CD4 counts less then 250 cells/mm[cubed] ". Recently there were public results on CE9.1 for severe asthma patients and I believe there were transient depletion of t-cells. It wouldn't surprise me if your source of info might have extrapolated from this study. Anyway, I tried to E-mail this and a bit more but for some reason it didn't get through. As I stated before one never knows until he/she knows when it comes to double blind placebo studies. Lets hope the stock can continue upwards.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next